Psilox AB is an innovative start-up company specialized in the manufacturing and application of cutting-edge bioceramic materials. The Company’s primary focus lies on life science applications, where the unique properties of our proprietary calcium phosphate microspheres can transform treatments in dentistry and medicine.
In India, the Pharmaceutical business of Psilox AB is focused on Hollow Calcium Phosphate particles, Ion substituted calcium phosphate particles.
Psilox AB filed patent application numbered 8442/DELNP/2015 that is titled as HOLLOW CALCIUM PHOSPHATE PARTICLES. This Patent Application has been granted as Patent Number 316589.
The invention covers Pharmaceuticals compound. The object of the invention is to provide hollow, and preferably porous, spherical CaP particles preferably without the use of strontium ions. This is achieved by a method comprising the steps:
a) Providing an aqueous buffer solution of purified water having a pH of 6-10 comprising 20-200 mM sodium ions, 0.1 -10 mM potassium ions and 1 -10 mM phosphate ions, and wherein the buffer solution is essentially free from strontium;
b) adding calcium ions in the range of from 0.1 to less than 2mM, and magnesium ions in the range of 0.01 -5 mM to the buffer solution and forming a mixture;
c) heating the mixture of step b) at 60-200 °C for at least 5 minutes;
d) isolating the formed particles; and
e)optionally washing the isolated particles using a suitable solvent.
The particles comprise 40-70 weight% of calcium, 20-40 weight% of phosphate and 1 -25 weight% magnesium. The Ca/P weight ratio is in the range of 1.10 to 1.90 and more than 80 % of the particles have a particle size between 200 to 1500 nm. The particles are essentially free from strontium. A composition comprising the particles may be used for remineralization of teeth or as bone void filling material.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act that it is not clear if the claimed combination act to provide an enhancement of the known efficacy w.r.t the known compound or combinations thereto.
As a response to the said objection, the applicant submits the applicant submits that without identifying the specific ‘known process’, neither can the Controller assert that the claimed process is a mere use of a known process’, nor can the Applicant accurately respond to the same.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
